Document is current
Any future updates will be listed below
-
Authors
De Giglio, Andrea
Leonetti, Alessandro
Comito, Francesca
Filippini, Daria Maria
Mollica, Veronica
Rihawi, Karim
Peroni, Marianna
Mazzaschi, Giulia
Ricciotti, Ilaria
Carosi, Francesca
Marchetti, Andrea
Rosellini, Matteo
Gagliano, Ambrogio
Favorito, Valentina
Nobili, Elisabetta
Gelsomino, Francesco
Melotti, Barbara
Marchese, Paola Valeria
Sperandi, Francesca
Di Federico, Alessandro
Buti, Sebastiano
Perrone, Fabiana
Massari, Francesco
Pantaleo, Maria Abbondanza
Tiseo, Marcello
Ardizzoni, Andrea
-
Funding
Funding for this research was provided by:
European Union - NextGeneration EU (PNRR - M4C2-I1.3 Project PE_00000019, CUP J33C22002920006)
Alma Mater Studiorum - Università di Bologna
- License Information
-
More Information
Article History
Received: 13 June 2024
Accepted: 15 September 2024
First Online: 3 October 2024
Declarations
:
: The authors declare no competing interests. ADF has received honoraria from Society for Immunotherapy of Cancer and Advisory role from Hansen-Wade. FM has received research support and/or honoraria from Astellas, BMS, Janssen, Ipsen, MSD and Pfizer outside the submitted work. AA has received Honoraria for the participation to advisory boards and/or for lectures from BMS, Eli-Lilly, MSD, AZ, Roche, Takeda, Janssen, Sanofi, Novartis, AbbVie, Daiichi. AL has received speakers’ fee for Astra-Zeneca, MSD, Takeda and Sanofi. AL has been on advisory board for BeiGene, Sanofi, Novartis, Astra-Zeneca. AL has attended editorial activities sponsored by Roche and Eli Lilly. AL has received travel support from MSD and Novartis. MT received speakers’ and consultants’ fee from Astra-Zeneca, Pfizer, Eli-Lilly, BMS, Novartis, Roche, MSD, Boehringer Ingelheim, Otsuka, Takeda, Pierre Fabre, Amgen, Merck, Sanofi. MT received institutional research grants from Astra-Zeneca, Boehringer Ingelheim.
